NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
作者信息
Valenti Luca, Nobili Valerio
机构信息
Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Policlinico Milano, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Hepatology, Gastroenterology and Nutrition Unit, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
出版信息
Hepatobiliary Surg Nutr. 2018 Dec;7(6):484-486. doi: 10.21037/hbsn.2018.10.03.
Abstract
摘要
相似文献
1
NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
Hepatobiliary Surg Nutr. 2018 Dec;7(6):484-486. doi: 10.21037/hbsn.2018.10.03.
2
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5.
3
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
J Hepatol. 2019 Apr;70(4):735-744. doi: 10.1016/j.jhep.2018.11.032. Epub 2018 Dec 8.
4
NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Hepatol Commun. 2018 Aug 30;2(9):1037-1050. doi: 10.1002/hep4.1209. eCollection 2018 Sep.
5
Serum ubiquitin levels in patients with nonalcoholic steatohepatitis.
Hepatogastroenterology. 2003 May-Jun;50(51):738-41.
6
Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial.
Am J Gastroenterol. 2018 May;113(5):725-734. doi: 10.1038/s41395-018-0042-7. Epub 2018 May 2.
7
Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Gastroenterol Hepatol (N Y). 2019 Feb;15(2):83-89.
8
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Curr Opin Endocrinol Diabetes Obes. 2018 Oct;25(5):315-320. doi: 10.1097/MED.0000000000000432.
9
Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
Exp Clin Transplant. 2016 Feb;14(1):79-85. doi: 10.6002/ect.2015.0089. Epub 2015 Nov 17.
10
Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
BMC Gastroenterol. 2016 Jun 13;16(1):61. doi: 10.1186/s12876-016-0477-5.
引用本文的文献
1
Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Int J Biol Sci. 2021 Jun 22;17(10):2576-2589. doi: 10.7150/ijbs.58776. eCollection 2021.
本文引用的文献
1
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease.
Liver Int. 2019 Feb;39(2):250-256. doi: 10.1111/liv.13972. Epub 2018 Oct 17.
2
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
3
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5.
4
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.
J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.
5
Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.
Liver Int. 2018 Feb;38(2):342-349. doi: 10.1111/liv.13531. Epub 2017 Aug 18.
6
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
7
Nuclear receptors and cholesterol metabolism in the intestine.
Atheroscler Suppl. 2015 Feb;17:9-11. doi: 10.1016/S1567-5688(15)50003-2.
8
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
9
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Cancer Res. 2014 Jun 15;74(12):3306-16. doi: 10.1158/0008-5472.CAN-14-0208. Epub 2014 Apr 11.
10
Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
PLoS One. 2013 Jun 26;8(6):e67160. doi: 10.1371/journal.pone.0067160. Print 2013.
Zotero 插件